Print

Cancer Research Consortium of West Michigan

Adult Cancer Prevention and Cancer Control Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Brain/CNS

Cancer Type: Brain Metastases
Research Base: NRG
Protocol: NRG CC001

NRG CC001: A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or Without Hippocampal Avoidance in Patients with Brain Metastases. 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Hi-Grade Glioma
Research Base: Alliance
Protocol: Alliance A221101

Alliance A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study. Armodafinil vs Placebo. Cancer-Related Fatigue in Patients with High Grade Glioma. 


 

Clinical Summary:

DCP-001 eligible study

Breast

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Clinical Summary:

DCP-001 eligible study

Cancer Type: Breast cancer
Research Base: ECOG-ACRIN
Protocol: EA1141

Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

Clinical Summary:

DCP-001 eligible study

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Clinical Summary:

Breast Cancer Weight Loss Study (BWEL) 

DCP-001 eligible study

Cancer Type: ER/PR+ Breast Cancer
Research Base: CTSU
Protocol: CTSU E1Z11

CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole. 
 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011104

Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Clinical Summary:

DCP-001 eligible study

Cancer Type: Stage I-III Breast or lymphoma
Research Base: Wake Forest
Protocol: WF 98213 - PREVENT

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo

Clinical Summary:

DCP-001 eligible study

Cancer Control

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Clinical Summary:

DCP-001 eligible study

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Clinical Summary:

Breast Cancer Weight Loss Study (BWEL) 

DCP-001 eligible study

Cancer Type: Cancer Care deliver
Research Base: SWOG
Protocol: SWOG S1415CD

A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia –Trial Assessing CSF Prescribing Effectiveness and Risk (“TrACER”)”

Clinical Summary:

DCP-001 eligible study

Cancer Type: Multisite
Research Base: ACCRU
Protocol: ACCRU RU221501I

ACCRU RU221501I: A Phase III, Randomized, Open label Study Evaluating the Safety of Apixaban in Subjects with Cancer Related Venous Thromboembolism (BMS# CV185-444)

Clinical Summary:

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Clinical Summary:

DCP-001 eligible study

Cancer Type: Breast cancer
Research Base: ECOG-ACRIN
Protocol: EA1141

Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

Clinical Summary:

DCP-001 eligible study

Cancer Type: Multisite - Screening
Research Base: NCI
Protocol: DCP-001
 

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Clinical Summary:

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S1417CD

S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer

Clinical Summary:

DCP-001 eligible study

Cancer Type: Symptom Management for Insomnia
Research Base: URCC
Protocol: URCC 14040 - YOCAS
 

URCC 14040: A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors

Clinical Summary:

DCP-001 eligible study

Cancer Type: Hi-Grade Glioma
Research Base: Alliance
Protocol: Alliance A221101

Alliance A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study. Armodafinil vs Placebo. Cancer-Related Fatigue in Patients with High Grade Glioma. 


 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 13059 (GAP 70)

URCC 13059 (GAP 70): A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults

Clinical Summary:

DCP-001 eligible study

Cancer Type: ER/PR+ Breast Cancer
Research Base: CTSU
Protocol: CTSU E1Z11

CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole. 
 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Head and Neck
Research Base: Wake Forest
Protocol: WF 97115

WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Stage I-III Breast or lymphoma
Research Base: Wake Forest
Protocol: WF 98213 - PREVENT

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo

Clinical Summary:

DCP-001 eligible study

Cancer Type: Ovarian, Fallopian Tube and Primary Peritoneal
Research Base: NRG
Protocol: GOG 0225

GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression Free Survival? Stage II-IV Ovarian, Fallopian Tube or Primary Peritoneal at diagnosis. Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks prior to enrollment and must be in complete remission. 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S0820

SWOG S0820: A Double Blind Placebo-Controlled Trial. Eflornithine vs Sulindac vs Elfornithine + Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers. Stage 0-III Colon Cancer, Phase III. 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Colorectal Stage IV
Research Base: NSABP-F
Protocol: NSABP MPR-1

NSABP MPR-1: Patient Registry and Biospecimen Profiling Repository. Stage IV Colorectal Cancer.

Clinical Summary:

Cancer Type: Brain Metastases
Research Base: NRG
Protocol: NRG CC001

NRG CC001: A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or Without Hippocampal Avoidance in Patients with Brain Metastases. 

Clinical Summary:

DCP-001 eligible study

Gastrointestinal

Cancer Type: Colorectal Stage IV
Research Base: NSABP-F
Protocol: NSABP MPR-1

NSABP MPR-1: Patient Registry and Biospecimen Profiling Repository. Stage IV Colorectal Cancer.

Clinical Summary:

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S0820

SWOG S0820: A Double Blind Placebo-Controlled Trial. Eflornithine vs Sulindac vs Elfornithine + Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers. Stage 0-III Colon Cancer, Phase III. 

Clinical Summary:

DCP-001 eligible study

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S1417CD

S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer

Clinical Summary:

DCP-001 eligible study

Gynecologic

Cancer Type: Ovarian, Fallopian Tube and Primary Peritoneal
Research Base: NRG
Protocol: GOG 0225

GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression Free Survival? Stage II-IV Ovarian, Fallopian Tube or Primary Peritoneal at diagnosis. Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks prior to enrollment and must be in complete remission. 

Clinical Summary:

DCP-001 eligible study

Head and Neck

Cancer Type: Head and Neck
Research Base: Wake Forest
Protocol: WF 97115

WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. 

Clinical Summary:

DCP-001 eligible study

Leukemia

Cancer Type: Myelodysplastic Syndromes
Research Base: ECOG-ACRIN
Protocol: NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Clinical Summary:

DCP-001 eligible study

Lung

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Clinical Summary:

DCP-001 eligible study

Multisite

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 13059 (GAP 70)

URCC 13059 (GAP 70): A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults

Clinical Summary:

DCP-001 eligible study

Cancer Type: Multisite - Screening
Research Base: NCI
Protocol: DCP-001
 

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Clinical Summary: